K’taka asks Centre to supply 25,000 doses of Amphotericin B as ‘black fungus’ cases rise
Team Udayavani, May 14, 2021, 10:12 AM IST
Bengaluru: With instances of mucormycosis, also known as the black fungus, coming to light among COVID-19 patients, the Karnataka government has asked the Centre to supply 25,000 doses of Amphotericin B.
“During the video conference Union Health Minister Dr Harsh Vardhan had with his counterparts in six states, we put forth a demand for 25,000 (doses of) Amphotericin B,” Karnataka Health Minister Dr K Sudhakar told reporters here.
The minister said due to the excess use of steroids and diabetes, cases of black fungus are being noticed as post-COVID complications.
“In Karnataka and Maharashtra such incidents happened,” Sudhakar said.
The only medicine to cure it is Amphotericin B, Sudhakar claimed, adding, the state government has placed order to purchase the anti-fungal drug.
According to doctors, mucormycosis, also called black fungus, is mostly found among COVID-19 patients who have diabetes.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
Top News
Related Articles More
Bidar: Police personnel suspended over negligence in tender scam case linked to contractor’s suicide
Gold fraud: Accused Aishwarya Gowda had defrauded doctor couple of Rs 6.2 crore
Madikeri: Police dogs Copper and Bruno win medals for cracking crime cases
Bengaluru: TV actor Charith Balappa arrested over sexual harassment allegations
Karnataka Cong pays tributes to Manmohan Singh at the venue planned for convention
MUST WATCH
Latest Additions
Bidar: Police personnel suspended over negligence in tender scam case linked to contractor’s suicide
Gold fraud: Accused Aishwarya Gowda had defrauded doctor couple of Rs 6.2 crore
Madikeri: Police dogs Copper and Bruno win medals for cracking crime cases
Bengaluru: TV actor Charith Balappa arrested over sexual harassment allegations
Karnataka Cong pays tributes to Manmohan Singh at the venue planned for convention
Thanks for visiting Udayavani
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.